Radiolabeled monoclonal antibodies in the treatment of non-Hodgkin's lymphoma.
The use of radiolabeled monoclonal antibodies in the treatment of non-Hodgkin's lymphoma offers the hope of delivering radiation to tumor with relative specificity, thereby providing significant antitumor effects with limited toxicity. In this article the results of recently initiated trials are summarized, and the major unresolved issues concerning this approach are reviewed.